The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

Checkpoint Inhibitors in Stage III NSCLC (Pacific Trial Regimen) / Biomarker Development and the Immune Landscape of Early Stage NSCLC

121 views
November 12, 2019
0 Comments
Login to view comments. Click here to Login
2019 Lung Cancer and Head & Neck Cancer Symposium